DE602004011781D1 - Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen - Google Patents

Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen

Info

Publication number
DE602004011781D1
DE602004011781D1 DE602004011781T DE602004011781T DE602004011781D1 DE 602004011781 D1 DE602004011781 D1 DE 602004011781D1 DE 602004011781 T DE602004011781 T DE 602004011781T DE 602004011781 T DE602004011781 T DE 602004011781T DE 602004011781 D1 DE602004011781 D1 DE 602004011781D1
Authority
DE
Germany
Prior art keywords
azd2171
human
azd
pharmaceutical preparations
preparations containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004011781T
Other languages
English (en)
Other versions
DE602004011781T2 (de
Inventor
Stephen Robert Wedge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE602004011781D1 publication Critical patent/DE602004011781D1/de
Application granted granted Critical
Publication of DE602004011781T2 publication Critical patent/DE602004011781T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602004011781T 2003-07-10 2004-07-07 Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen Expired - Fee Related DE602004011781T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0316123.9A GB0316123D0 (en) 2003-07-10 2003-07-10 Combination therapy
GB0316123 2003-07-10
PCT/GB2004/002937 WO2005004871A1 (en) 2003-07-10 2004-07-07 Combination therapy

Publications (2)

Publication Number Publication Date
DE602004011781D1 true DE602004011781D1 (de) 2008-03-27
DE602004011781T2 DE602004011781T2 (de) 2009-02-19

Family

ID=27741905

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004011781T Expired - Fee Related DE602004011781T2 (de) 2003-07-10 2004-07-07 Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen

Country Status (18)

Country Link
US (1) US20060160775A1 (de)
EP (1) EP1651227B1 (de)
JP (1) JP2007526887A (de)
KR (1) KR20060034287A (de)
CN (1) CN100435799C (de)
AT (1) ATE385798T1 (de)
AU (1) AU2004255023B2 (de)
BR (1) BRPI0412450A (de)
CA (1) CA2531643A1 (de)
DE (1) DE602004011781T2 (de)
ES (1) ES2299841T3 (de)
GB (1) GB0316123D0 (de)
HK (1) HK1089384A1 (de)
IL (1) IL172682A0 (de)
MX (1) MXPA06000413A (de)
NO (1) NO20056171L (de)
WO (1) WO2005004871A1 (de)
ZA (1) ZA200600188B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
WO2005092384A2 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy with azd2171 and a platinum anti-tumour agent
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
EP1901754A2 (de) * 2005-07-06 2008-03-26 AstraZeneca AB Kombinationstherapie gegen krebs mit azd2171 und gemcitabin
NZ568812A (en) * 2005-12-22 2011-09-30 Astrazeneca Ab Combination of AZD2171 and pemetrexed
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
AU762615B2 (en) * 1998-06-15 2003-07-03 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
DK1553097T3 (da) * 1999-02-10 2010-12-13 Astrazeneca Ab Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
AU2001242586B2 (en) * 2000-03-31 2004-12-16 Angiogene Pharmaceuticals Ltd. Divided dose therapies with vascular damaging activity
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy

Also Published As

Publication number Publication date
JP2007526887A (ja) 2007-09-20
HK1089384A1 (en) 2006-12-01
KR20060034287A (ko) 2006-04-21
WO2005004871A1 (en) 2005-01-20
EP1651227A1 (de) 2006-05-03
AU2004255023B2 (en) 2007-09-27
IL172682A0 (en) 2006-04-10
ATE385798T1 (de) 2008-03-15
US20060160775A1 (en) 2006-07-20
DE602004011781T2 (de) 2009-02-19
ZA200600188B (en) 2007-04-25
CN100435799C (zh) 2008-11-26
GB0316123D0 (en) 2003-08-13
CA2531643A1 (en) 2005-01-20
EP1651227B1 (de) 2008-02-13
NO20056171L (no) 2006-02-07
AU2004255023A1 (en) 2005-01-20
MXPA06000413A (es) 2006-03-17
ES2299841T3 (es) 2008-06-01
BRPI0412450A (pt) 2006-09-19
CN1819830A (zh) 2006-08-16

Similar Documents

Publication Publication Date Title
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
ATE500832T1 (de) Kombination von zd6474 und pemetrexed
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
HK1089384A1 (en) Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
NO20064754L (no) Kombinasjonsterapi
DE60308403D1 (de) Kombinationstherapie mit gemzitabin und zd6126

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee